ARAF and non-small cell lung carcinoma: Here we extend this observation to show that both BRAF and CRAF, but not ARAF knockdown, impair ERK-pathway reactivation and sensitize KRAS-mutant NSCLC cell lines to MEKi, although not as strongly as SHOC2 KD (Fig. 5).